Publications

Nature medicine

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.

01-12-2020

Key

Cancer treatment reviews

Local administration of immunotherapy for patients with skin cancer: A systematic review.

01-12-2024

Immuno-oncology technology

Integrated noninvasive diagnostics for prediction of survival in immunotherapy.

01-12-2024

European journal of cancer (Oxford, England : 1990)

Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo.

19-11-2024

Cell host & microbe

Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients.

13-11-2024

Annals of oncology : official journal of the European Society for Medical Oncology

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

13-11-2024

JCI insight

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.

08-11-2024

The New England journal of medicine

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

07-11-2024

European journal of cancer (Oxford, England : 1990)

Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.

01-11-2024

European journal of cancer (Oxford, England : 1990)

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

01-11-2024

Nature medicine

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

01-11-2024

European journal of cancer (Oxford, England : 1990)

Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy.

01-11-2024

International journal of cancer

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.

15-10-2024

Cancer cell

Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8⁺ T cells.

09-09-2024

The Lancet. Oncology

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

01-09-2024

Journal of experimental & clinical cancer research : CR

Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy.

21-08-2024

European journal of cancer (Oxford, England : 1990)

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

01-08-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

01-08-2024

JAMA network open

Long-Term Survival in Patients With Advanced Melanoma.

01-08-2024

Cancers

Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.

26-07-2024

BMC cancer

Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.

23-05-2024

International journal of cancer

A prediction model for response to immune checkpoint inhibition in advanced melanoma.

15-05-2024

Cancer

BRAF/MEK inhibitor rechallenge in advanced melanoma patients.

01-05-2024

Journal for immunotherapy of cancer

Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.

27-04-2024

European journal of cancer (Oxford, England : 1990)

Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

01-04-2024

European journal of cancer (Oxford, England : 1990)

The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.

01-03-2024

EClinicalMedicine

Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021.

01-03-2024

Journal for immunotherapy of cancer

Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.

31-01-2024

Cancer immunology, immunotherapy : CII

Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma.

27-01-2024

European journal of cancer (Oxford, England : 1990)

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.

01-01-2024

Pigment cell & melanoma research

Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort.

01-01-2024

Nature medicine

Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.

01-12-2023

Cancers

Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period.

15-11-2023

Cancer immunology, immunotherapy : CII

Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.

01-11-2023

Cancer discovery

Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma.

01-11-2023

Cancer cell

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.

09-10-2023

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Health-state utilities in long-term advanced melanoma survivors comparable with the general population.

01-09-2023

European journal of cancer (Oxford, England : 1990)

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

01-08-2023

International journal of cancer

Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials.

15-07-2023

Journal for immunotherapy of cancer

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.

01-07-2023

The Lancet. Oncology

Adjuvant immune checkpoint blockade revisited.

01-07-2023

International journal of cancer

Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.

15-06-2023

European journal of cancer (Oxford, England : 1990)

Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies.

01-06-2023

European journal of immunology

Acidity-mediated induction of FoxP3⁺ regulatory T cells.

01-06-2023

Cancer chemotherapy and pharmacology

Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients.

01-06-2023

Nature medicine

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.

01-06-2023

Journal of immunotherapy (Hagerstown, Md. : 1997)

Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.

01-06-2023

Nature reviews. Clinical oncology

Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma.

01-06-2023

Cancers

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.

26-05-2023

The Journal of experimental medicine

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.

01-05-2023